Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45


Transducin-Like Enhancer of Split 3 (TLE3) expression is associated with taxane sensitivity in non-serous ovarian carcinoma in a three-cohort study.

Ring BZ, Murali R, Soslow RA, Bowtell DDL, Fereday S, DeFazio A, Traficante N, Kennedy CJ, Brand A, Sharma R, Harnett P, Samimi G.

Cancer Epidemiol Biomarkers Prev. 2018 Mar 12. pii: cebp.1101.2017. doi: 10.1158/1055-9965.EPI-17-1101. [Epub ahead of print]


Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.

Samimi G, Trabert B, Duggan MA, Robinson JL, Coa KI, Waibel E, Garcia E, Minasian LM, Sherman ME.

Gynecol Oncol. 2018 Mar;148(3):515-520. doi: 10.1016/j.ygyno.2018.01.016.


Traceback: leveraging archived biospecimens to identify mutation carriers.

Samimi G, Sherman ME.

Oncotarget. 2017 Oct 11;8(53):90628-90629. doi: 10.18632/oncotarget.21742. eCollection 2017 Oct 31. No abstract available.


Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach.

Moss HA, Samimi G, Havrilesky LJ, Sherman ME, Myers ER.

Genet Epidemiol. 2018 Feb;42(1):117-122. doi: 10.1002/gepi.22095. Epub 2017 Nov 30.


Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.

Temkin SM, Miller EA, Samimi G, Berg CD, Pinsky P, Minasian L.

Eur J Cancer. 2017 Dec;87:182-188. doi: 10.1016/j.ejca.2017.10.015. Epub 2017 Nov 21.


Ovarian Cancer Prevention in High-risk Women.

Temkin SM, Bergstrom J, Samimi G, Minasian L.

Clin Obstet Gynecol. 2017 Dec;60(4):738-757. doi: 10.1097/GRF.0000000000000318.


Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis.

Vafaee F, Colvin EK, Mok SC, Howell VM, Samimi G.

Sci Rep. 2017 Sep 4;7(1):10374. doi: 10.1038/s41598-017-10869-y.


Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.

Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai PL, Mechanic LE, Minasian LM, Myers ER, Robson ME, Ramus SJ, Rezende LF, Shaw PA, Slavin TP, Swisher EM, Takenaka M, Bowtell DD, Sherman ME.

J Clin Oncol. 2017 Jul 10;35(20):2329-2337. doi: 10.1200/JCO.2016.70.3439. Epub 2017 Apr 11.


Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer?

Samimi G, Minasian LM.

Cancer. 2017 May 15;123(10):1699-1702. doi: 10.1002/cncr.30525. Epub 2017 Mar 23. No abstract available.


Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Sherman ME, Drapkin RI, Horowitz NS, Crum CP, Friedman S, Kwon JS, Levine DA, Shih IeM, Shoupe D, Swisher EM, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, Minasian LM.

Cancer Prev Res (Phila). 2016 Sep;9(9):713-20. doi: 10.1158/1940-6207.CAPR-15-0384. Epub 2016 May 24. Review.


Methylated circulating tumor DNA in blood: power in cancer prognosis and response.

Warton K, Mahon KL, Samimi G.

Endocr Relat Cancer. 2016 Mar;23(3):R157-71. doi: 10.1530/ERC-15-0369. Epub 2016 Jan 13. Review.


Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.

Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ, Samimi G.

Oncotarget. 2015 Dec 29;6(42):44551-62. doi: 10.18632/oncotarget.6082.


Methylation of cell-free circulating DNA in the diagnosis of cancer.

Warton K, Samimi G.

Front Mol Biosci. 2015 Apr 22;2:13. doi: 10.3389/fmolb.2015.00013. eCollection 2015. Review.


Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasma.

Warton K, Lin V, Navin T, Armstrong NJ, Kaplan W, Ying K, Gloss B, Mangs H, Nair SS, Hacker NF, Sutherland RL, Clark SJ, Samimi G.

BMC Genomics. 2014 Jun 15;15:476. doi: 10.1186/1471-2164-15-476.


ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer.

Gloss B, Moran-Jones K, Lin V, Gonzalez M, Scurry J, Hacker NF, Sutherland RL, Clark SJ, Samimi G.

Mol Cancer. 2014 Jan 6;13:3. doi: 10.1186/1476-4598-13-3.


Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment.

Scott CL, Becker MA, Haluska P, Samimi G.

Front Oncol. 2013 Dec 4;3:295. doi: 10.3389/fonc.2013.00295. Review.


TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.

Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC.

Cancer Res. 2013 Aug 15;73(16):5016-28. doi: 10.1158/0008-5472.CAN-13-0023. Epub 2013 Jul 3.


Epigenetic biomarkers in epithelial ovarian cancer.

Gloss BS, Samimi G.

Cancer Lett. 2014 Jan 28;342(2):257-63. doi: 10.1016/j.canlet.2011.12.036. Epub 2012 Jan 12. Review.


TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.

Samimi G, Ring BZ, Ross DT, Seitz RS, Sutherland RL, O'Brien PM, Hacker NF, Huh WK.

Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):273-9. doi: 10.1158/1055-9965.EPI-11-0917. Epub 2011 Dec 22.


Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.

Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM.

Gynecol Oncol. 2012 Mar;124(3):582-8. doi: 10.1016/j.ygyno.2011.11.026. Epub 2011 Nov 22.


Up-regulation of stromal versican expression in advanced stage serous ovarian cancer.

Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS, Mok SC.

Gynecol Oncol. 2010 Oct;119(1):114-20. doi: 10.1016/j.ygyno.2010.05.029. Epub 2010 Jul 8.


A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ.

Cancer Cell. 2009 Dec 8;16(6):521-32. doi: 10.1016/j.ccr.2009.10.018.


Cell cycle and related protein.

Farley J, Ozbun L, Samimi G, Birrer MJ.

Dis Markers. 2007;23(5-6):433-43. Review. No abstract available.


Biomarkers of mucinous tumors of the ovary.

Samimi G, Ozbun L, Johnson ME, Mok SC, Birrer MJ.

Dis Markers. 2007;23(5-6):389-96. No abstract available.


Etiology and pathogenesis of epithelial ovarian cancer.

Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK.

Dis Markers. 2007;23(5-6):367-76. Review.


Measures of energy balance and mammographic density in the Nurses' Health Study.

Samimi G, Colditz GA, Baer HJ, Tamimi RM.

Breast Cancer Res Treat. 2008 May;109(1):113-22. Epub 2007 Jun 26.


Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.

Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB.

Cancer Chemother Pharmacol. 2007 Feb;59(3):301-12. Epub 2006 Jun 13.


Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.

Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB.

Cancer Chemother Pharmacol. 2006 Sep;58(3):384-95. Epub 2006 Jan 11.


Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.

Samimi G, Howell SB.

Cancer Chemother Pharmacol. 2006 Jun;57(6):781-8. Epub 2005 Sep 17.


Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells.

Safaei R, Katano K, Larson BJ, Samimi G, Holzer AK, Naerdemann W, Tomioka M, Goodman M, Howell SB.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):756-67.


The role of copper transporters in the development of resistance to Pt drugs.

Safaei R, Holzer AK, Katano K, Samimi G, Howell SB.

J Inorg Biochem. 2004 Oct;98(10):1607-13. Review.


cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance.

Samimi G, Manorek G, Castel R, Breaux JK, Cheng TC, Berry CC, Los G, Howell SB.

Cancer Chemother Pharmacol. 2005 Jan;55(1):1-11. Epub 2004 Sep 16.


Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.

Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB.

Clin Cancer Res. 2004 Jul 15;10(14):4661-9.


Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells.

Katano K, Safaei R, Samimi G, Holzer A, Tomioka M, Goodman M, Howell SB.

Clin Cancer Res. 2004 Jul 1;10(13):4578-88.


The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.

Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, Howell SB.

Mol Pharmacol. 2004 Oct;66(4):817-23. Epub 2004 Jun 30.


Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.

Samimi G, Katano K, Holzer AK, Safaei R, Howell SB.

Mol Pharmacol. 2004 Jul;66(1):25-32.


Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.

Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, Howell SB.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5853-9.


Cross-resistance to cisplatin in cells with acquired resistance to copper.

Safaei R, Katano K, Samimi G, Naerdemann W, Stevenson JL, Rochdi M, Howell SB.

Cancer Chemother Pharmacol. 2004 Mar;53(3):239-46. Epub 2003 Nov 28.


The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells.

Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB.

Mol Pharmacol. 2003 Aug;64(2):466-73.


Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.

Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB.

Cancer Res. 2002 Nov 15;62(22):6559-65.


The cellular pharmacology of oxaliplatin resistance.

Mishima M, Samimi G, Kondo A, Lin X, Howell SB.

Eur J Cancer. 2002 Jul;38(10):1405-12.


Using mRNA expression profiling to determine anticancer drug efficacy.

Los G, Yang F, Samimi G, Manorek G, Guerorguieva IM, Howell S, van Erp N, Breaux JK.

Cytometry. 2002 Jan 1;47(1):66-71.


Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.

Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS, Howell SB.

Clin Cancer Res. 2000 Apr;6(4):1415-21.

Supplemental Content

Loading ...
Support Center